Correlation of Parkinson disease severity and 18F-DTBZ positron emission tomography (JAMA Neurology (2014) 71, 6 (758-766) DOI: 10.1001/jamaneurol.2014.290);Correlation of parkinson disease severity and 18F-DTBZ positron emission tomography

JAMA Neurology

Volumn 71, Issue 6, 2014, Pages 758-766

  Hsiao, Ing Tsung ^a,b,c   Weng, Yi Hsin ^c,d   Hsieh, Chia Ju ^a,b   Lin, Wey Yil ^c   Wey, Shiaw Pyng ^a,b,c   Kung, Mei Ping ^a,b,e   Yen, Tzu Chen ^b,c   Lu, Chin Song ^b,c   Lin, Kun Ju ^a,b,c  

^a CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

^b CHANG GUNG UNIVERSITY   (Taiwan)

^c CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^d CHANG GUNG UNIVERSITY   (Taiwan)

^e UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AV 133; FLORBENAZINE F 18; UNCLASSIFIED DRUG; VESICULAR MONOAMINE TRANSPORTER 2;

ADULT; AGED; AKINESIA; ARTICLE; BALANCE IMPAIRMENT; CAUDATE NUCLEUS; CONTROLLED STUDY; DISEASE DURATION; DISEASE SEVERITY; FEMALE; GAIT DISORDER; HOEHN AND YAHR SCALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MUSCLE RIGIDITY; PARKINSON DISEASE; PET-CT SCANNER; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PUTAMEN; SUBSTANTIA NIGRA; TAIWAN; TREMOR; UNIFIED PARKINSON DISEASE RATING SCALE;

ADULT; AGED; FEMALE; FLUORINE RADIOISOTOPES; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; MALE; MIDDLE AGED; MUSCLE RIGIDITY; PARKINSON DISEASE; POSITRON-EMISSION TOMOGRAPHY; TETRABENAZINE; TREMOR;

EID: 84902206494     PISSN: 21686149     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamaneurol.2014.290     Document Type: Erratum

References (54)

1. Braak H, Rub U, Gai WP, Del Tredici K. Idiopathic Parkinson's disease: possible routes by which vulnerable neuronal typesmay be subject to neuroinvasion by an unknown pathogen. J Neural Transm. 2003;110(5):517-536 (Pubitemid 36543283)
2. Gelb DJ, Oliver E, Gilman S. Diagnostic criteria for Parkinson disease. Arch Neurol. 1999;56(1):33-39 (Pubitemid 29046907)
3. Calne DB, Snow BJ, Lee C. Criteria for diagnosing Parkinson's disease. Ann Neurol. 1992;32(S1) (suppl):S125-S127
4. Seibyl JP, Marek KL, Quinlan D, et al. Decreased single-photon emission computed tomographic [123I]β-CIT striatal uptake correlates with symptom severity in Parkinson's disease [published correction appears in Ann Neurol. 1996;39(3):417]. Ann Neurol. 1995;38(4):589-598
5. Bao SY,Wu JC, LuoWF, Fang P, Liu ZL, Tang J. Imaging of dopamine transporters with technetium-99mTRODAT-1 and single photon emission computed tomography. J Neuroimaging. 2000;10(4):200-203
6. HuangWS, LeeMS, Lin JC, et al. Usefulness of brain 99mTc-TRODAT-1 SPET for the evaluation of Parkinson's disease. Eur J Nucl Med Mol Imaging. 2004;31(2):155-161
7. Weng YH, Yen TC, Chen MC, et al. Sensitivity and specificity of 99mTc-TRODAT-1 SPECT imaging in differentiating patients with idiopathic Parkinson's disease from healthy subjects. J Nucl Med. 2004;45 (3):393-401
8. Antonini A, Vontobel P, Psylla M, et al. Complementary positron emission tomographic studies of the striatal dopaminergic system in Parkinson's disease. Arch Neurol. 1995;52(12): 1183-1190
9. Morrish PK, Sawle GV, Brooks DJ. An [18F]dopa-PET and clinical study of the rate of progression in Parkinson's disease. Brain. 1996; 119(pt 2):585-591
10. Brooks DJ, Frey KA, Marek KL, et al. Assessment of neuroimaging techniques as biomarkers of the progression of Parkinson's disease. Exp Neurol. 2003;184(suppl 1):S68-S79 (Pubitemid 37338706)
11. 18F]fluorodopa positron emission tomographic studies. Mov Disord. 1990;5(3):203-213 (Pubitemid 20311769)
12. Vingerhoets FJG, SchulzerM, Calne DB, Snow BJ. Which clinical sign of Parkinson's disease best reflects the nigrostriatal lesion? Ann Neurol. 1997;41 (1):58-64
13. Fahn S, Oakes D, Shoulson I, et al Parkinson Study Group. Levodopa and the progression of Parkinson's disease. N Engl J Med. 2004;351(24): 2498-2508
14. Ahlskog JE, Maraganore DM, Uitti RJ, Uhl GR. Brain imaging to assess the effects of dopamine agonists on progression of Parkinson disease. JAMA. 2002;288(3):311-313, author reply 312-313
15. Marek K, Seibyl J, Shoulson I, et al Parkinson Study Group. Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson disease progression. JAMA. 2002;287 (13):1653-1661 (Pubitemid 34289217)
16. Lee CS, Samii A, Sossi V, et al. In vivo positron emission tomographic evidence for compensatory changes in presynaptic dopaminergic nerve terminals in Parkinson's disease. Ann Neurol. 2000; 47(4):493-503 (Pubitemid 30194606)
17. Nandhagopal R, Kuramoto L, SchulzerM, et al. Longitudinal evolution of compensatory changes in striatal dopamine processing in Parkinson's disease. Brain. 2011;134(pt 11):3290-3298
18. Ahlskog JE. Slowing Parkinson's disease progression: recent dopamine agonist trials. Neurology. 2003;60(3):381-389 (Pubitemid 36188230)
19. Gilman S, Koeppe RA, Adams KM, et al. Decreased striatal monoaminergic terminals in severe chronic alcoholism demonstrated with (+)[11C] dihydrotetrabenazine and positron emission tomography. Ann Neurol. 1998;44(3): 326-333 (Pubitemid 28421436)
20. de la Fuente-Fernandez R, Sossi V, McCormick S, SchulzerM, Ruth TJ, Stoessl AJ. Visualizing vesicular dopamine dynamics in Parkinson's disease. Synapse. 2009;63(8):713-716
21. Vander Borght T, KilbournM, Desmond T, Kuhl D, Frey K. The vesicular monoamine transporter is not regulated by dopaminergic drug treatments. Eur J Pharmacol. 1995;294(2-3):577-583 (Pubitemid 26016763)
22. Kemmerer ES, Desmond TJ, Albin RL, Kilbourn MR, Frey KA. Treatment effects on nigrostriatal projection integrity in partial 6-OHDA lesions: comparison of L-DOPA and pramipexole. Exp Neurol. 2003;183(1):81-86 (Pubitemid 37075859)
23. Wilson JM, Kish SJ. The vesicular monoamine transporter, in contrast to the dopamine transporter, is not altered by chronic cocaine self-administration in the rat. J Neurosci. 1996;16 (10):3507-3510 (Pubitemid 26142379)
24. KilbournMR, Frey KA, Vander Borght T, Sherman PS. Effects of dopaminergic drug treatments on in vivo radioligand binding to brain vesicular monoamine transporters. Nucl Med Biol. 1996;23(4):467-471 (Pubitemid 26233217)
25. Bohnen NI, Albin RL, Koeppe RA, et al. Positron emission tomography of monoaminergic vesicular binding in aging and Parkinson disease. J Cereb Blood Flow Metab. 2006;26(9):1198-1212 (Pubitemid 44268182)
26. Blesa J, Juri C, Collantes M, et al. Progression of dopaminergic depletion in a model of MPTP-induced Parkinsonism in non-human primates: an (18)F-DOPA and (11)C-DTBZ PET study. Neurobiol Dis. 2010;38(3):456-463
27. Goswami R, Ponde DE, KungMP, Hou C, KilbournMR, Kung HF. Fluoroalkyl derivatives of dihydrotetrabenazine as positron emission tomography imaging agents targeting vesicular monoamine transporters. Nucl Med Biol. 2006;33 (6):685-694 (Pubitemid 44247731)
28. Okamura N, Villemagne VL, Drago J, et al. In vivo measurement of vesicular monoamine transporter type 2 density in Parkinson disease with (18)F-AV-133. J Nucl Med. 2010;51(2):223-228
29. Lin KJ, LinWY, Hsieh CJ, et al. Optimal scanning time window for 18F-FP-(+)-DTBZ (18F-AV-133) summed uptake measurements. Nucl Med Biol. 2011;38(8):1149-1155
30. Lin KJ,Weng YH, Hsieh CJ, et al. Brain imaging of vesicular monoamine transporter type 2 in healthy aging subjects by 18F-FP-(+)-DTBZ PET. PLoS One. 2013;8(9):e75952
31. Lozano AM, Lang AE, Galvez-Jimenez N, et al. Effect of GPi pallidotomy on motor function in Parkinson's disease. Lancet. 1995;346(8987): 1383-1387
32. Carson RE. PET physiological measurements using constant infusion. Nucl Med Biol. 2000;27(7): 657-660
33. Tsao HH, Lin KJ, Juang JH, et al. Binding characteristics of 9-fluoropropyl-(+)- dihydrotetrabenzazine (AV-133) to the vesicular monoamine transporter type 2 in rats. Nucl Med Biol. 2010;37(4):413-419
34. Mazziotta JC, Toga AW, Evans A, Fox P, Lancaster J; The International Consortium for Brain Mapping (ICBM). A probabilistic atlas of the human brain: theory and rationale for its development. Neuroimage. 1995;2(2):89-101
35. Andringa G, Eshuis S, Perentes E, et al. TCH346 prevents motor symptoms and loss of striatal FDOPA uptake in bilaterally MPTP-treated primates. Neurobiol Dis. 2003;14(2):205-217 (Pubitemid 37311285)
36. Nandhagopal R, Kuramoto L, SchulzerM, et al. Longitudinal progression of sporadic Parkinson's disease: a multi-tracer positron emission tomography study. Brain. 2009;132(pt 11): 2970-2979
37. Holmes D. Jon Stoessl: besotted with the brain. Lancet Neurol. 2011;10(11):955
38. Tong J, Boileau I, Furukawa Y, et al. Distribution of vesicular monoamine transporter 2 protein in human brain: implications for brain imaging studies. J Cereb Blood Flow Metab. 2011;31(10):2065-2075
39. Scherman D, Raisman R, Ploska A, Agid Y. [3H]dihydrotetrabenazine, a new in vitro monoaminergic probe for human brain. J Neurochem. 1988;50(4):1131-1136
40. Hornykiewicz O. Biochemical aspects of Parkinson's disease. Neurology. 1998;51(2)(suppl 2):S2-S9 (Pubitemid 28397136)
41. Fearnley JM, Lees AJ. Ageing and Parkinson's disease: substantia nigra regional selectivity. Brain. 1991;114(pt 5):2283-2301
42. Damier P, Hirsch EC, Agid Y, Graybiel AM. The substantia nigra of the human brain, II: patterns of loss of dopamine-containing neurons in Parkinson's disease. Brain. 1999;122(Pt 8):1437-1448 (Pubitemid 29374122)
43. Martin WR,WielerM, Stoessl AJ, SchulzerM. Dihydrotetrabenazine positron emission tomography imaging in early, untreated Parkinson's disease. Ann Neurol. 2008;63(3):388-394 (Pubitemid 351499868)
44. Kish SJ, Shannak K, Hornykiewicz O. Uneven pattern of dopamine loss in the striatum of patients with idiopathic Parkinson's disease: pathophysiologic and clinical implications. N Engl J Med. 1988;318(14):876-880 (Pubitemid 18090271)
45. Bernheimer H, BirkmayerW, Hornykiewicz O, Jellinger K, Seitelberger F. Brain dopamine and the syndromes of Parkinson and Huntington: clinical, morphological and neurochemical correlations. J Neurol Sci. 1973;20(4):415-455
46. Lehericy S, Brandel JP, Hirsch EC, et al. Monoamine vesicular uptake sites in patients with Parkinson's disease and Alzheimer's disease, as measured by tritiated dihydrotetrabenazine autoradiography. Brain Res. 1994;659(1-2):1-9 (Pubitemid 24292838)
47. GibbWR, Fearnley JM, Lees AJ. The anatomy and pigmentation of the human substantia nigra in relation to selective neuronal vulnerability. Adv Neurol. 1990;53:31-34
48. HuangWS, Lin SZ, Lin JC,Wey SP, Ting G, Liu RS. Evaluation of early-stage Parkinson's disease with 99mTc-TRODAT-1 imaging. J Nucl Med. 2001; 42(9):1303-1308 (Pubitemid 32852603)
49. Zubieta JK, Huguelet P, Ohl LE, et al. High vesicular monoamine transporter binding in asymptomatic bipolar I disorder: sex differences and cognitive correlates. Am J Psychiatry. 2000;157 (10):1619-1628
50. PirkerW. Correlation of dopamine transporter imaging with parkinsonian motor handicap: how close is it? Mov Disord. 2003;18(suppl 7):S43-S51 (Pubitemid 37336928)
51. Benamer HT, Patterson J,Wyper DJ, Hadley DM, Macphee GJ, Grosset DG. Correlation of Parkinson's disease severity and duration with 123I-FP-CIT SPECT striatal uptake. Mov Disord. 2000;15(4):692-698 (Pubitemid 30479622)
52. Broussolle E, Dentresangle C, Landais P, et al. The relation of putamen and caudate nucleus 18F-Dopa uptake to motor and cognitive performances in Parkinson's disease. J Neurol Sci. 1999;166(2):141-151 (Pubitemid 29339086)
53. Abe Y, Kachi T, Kato T, et al. Occipital hypoperfusion in Parkinson's disease without dementia: correlation to impaired cortical visual processing. J Neurol Neurosurg Psychiatry. 2003;74 (4):419-422 (Pubitemid 36379360)
54. Bohnen NI,Minoshima S, Giordani B, Frey KA, Kuhl DE. Motor correlates of occipital glucose hypometabolism in Parkinson's disease without dementia. Neurology. 1999;52(3):541-546. (Pubitemid 29075600)